Eluminex Biosciences
Look better. See better. Eluminex specializes in advanced engineered protein therapeutics for dermal facial aesthetics, regenerative medicine, and retinal disease. Only company to produce full-length triple helix recombinant human type III collagen for dermal facial aesthetics and regenerative medicine. learn more Only company to produce trispecific recombinant …
About Us - Eluminex Biosciences (典晶生物)
Eluminex is dedicated towards developing first- and/or best-in-class protein therapeutics to enhance people lives and become a global leader in collagen-based aesthetics/ regenerative medicine and treatment for vision threatening diseases. Eluminex Biosciences is a privately-held biotechnology company founded in early 2020. The leadership team comprises over 150 years …
Management Team - Eluminex Biosciences (典晶生物)
Charles Semba serves as the company’s Chief Medical Officer (CMO). With more than 20 years in ophthalmic research and drug development, Dr. Semba has served as CMO in three prior ophthalmic companies: SARcode Bioscience (acquired by Shire/Takeda), ForSight VISION5 (acquired by Allergan), and Graybug Vision (NASDAQ: GRAY).
Eluminex Biosciences
2023年12月19日，提供全球最大独角兽和未来独角兽榜单的胡润研究院首次发布 “全球猎豹企业榜”。《2023胡润全球猎豹企业榜》(Hurun Global Cheetah Index 2023) 列出了全球成立于2000年之后，五年内最有可能达到独角兽级十亿美金估值的747家高成长性企业，包括291家中国企业。
Eluminex Biosciences Announces FDA Acceptance of …
Apr 30, 2024 · SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ — Eluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development of advanced protein therapeutics for vision-threatening diseases and dermal facial aesthetics announced the acceptance of their EB-105 IND application to the US Food and …
Ophthalmics Pipeline - Eluminex Biosciences (典晶生物)
EB-301 G2 Full Length Triple Helix rhCIII; Prevent Corneal Blindness; Preclinical. EB-301 G2 is a novel first-in-class biosynthetic cornea device mainly made from full-length, triple helix recombinant human Type III collagen (rhCIII) and is in preclinical development stage initially for the China market.
Eluminex Biosciences Closes $40+ Million Series B Financing
Feb 28, 2023 · Series B Proceeds Will Enable Continued Development of Innovative . Ophthalmic Assets and Recombinant Human Collagen Technology. Suzhou, China, February 28, 2023 / San Francisco, USA (PR Newswire) – Eluminex Biosciences (Suzhou) Limited (Eluminex) officially announced today the closing of a Series B financing of over $40 million (USD). Financing was …